Entrectinib Suppliers list
Company Name: Shanghai Payne Pharmaceutical Technology Co.Ltd
Tel: 021-58123769
Email: info@paynepharm.com
Products Intro: Product Name:Entrectinib
Purity:99% HPLC Package:1G;50G;100G;1KG
Tel: +86 21 5161 9050/ 5187 7795
Email: ivan@atkchemical.com
Products Intro: Product Name:Entrectinib,NMS-E628,RXDX-101
Purity:98% HPLC Package:5MG;10MG;50MG;100MG,1G,5G
Company Name: career henan chemical co
Tel: +86-371-86658258
Email: sales@coreychem.com
Products Intro: Product Name:Entrectinib
Purity:99% Package:1kg;2USD
Company Name: TianYuan Pharmaceutical CO.,LTD
Tel: +86-755-23284190 13684996853
Email: sales@tianpharm.com
Products Intro: Product Name:Entrectinib
Purity:99% Package:10g 100g 200g 500g 1kg 5kg per barrel
Company Name: Biochempartner
Tel: 0086-13720134139
Email: candy@biochempartner.com
Products Intro: Product Name:Entrectinib
Purity:98% HPLC LCMS Package:10G;20G

Lastest Price from Entrectinib manufacturers

  • Entrectinib
  • US $0.00-0.00 / g
  • 2021-10-08
  • CAS:1108743-60-7
  • Min. Order: 1g
  • Purity: 98%
  • Supply Ability: 100kgs
  • BMN 673
  • US $15.00-10.00 / KG
  • 2021-07-13
  • CAS:1108743-60-7
  • Min. Order: 1KG
  • Purity: 99%+ HPLC
  • Supply Ability: Monthly supply of 1 ton
  • BMN 673
  • US $15.00-10.00 / KG
  • 2021-07-10
  • CAS:1108743-60-7
  • Min. Order: 1KG
  • Purity: 99%+ HPLC
  • Supply Ability: Monthly supply of 1 ton

Related articles

  • Entratinib's mechanism of action
  • Entritinib was approved for marketing in Japan on June 19, 2019, and was approved by the FDA on August 15, 2019 for the treatm....
  • Oct 26,2020
Entrectinib Basic information
Description Effect and benefit Mechanism of action Safety Pharmacology
Product Name:Entrectinib
Product Categories:API;API
Mol File:1108743-60-7.mol
Entrectinib Structure
Entrectinib Chemical Properties
Boiling point 717.5±60.0 °C(Predicted)
density 1.340±0.06 g/cm3(Predicted)
Safety Information
MSDS Information
Entrectinib Usage And Synthesis
DescriptionEntrectinib is used to treat metastatic (lung cancer that has already spread) non-small cell lung cancer (NSCLC) that is caused by a gene called ROS1. This medicine is also used to treat solid tumors (cancer) that are caused by certain abnormal NTRK genes and have spread or if surgery to remove the cancer is likely to cause severe complications, and there is no acceptable treatment option or the cancer grew or spread on other treatments.
Effect and benefitEntrectinib belongs to the group of medicines called antineoplastics (cancer medicines). It works by interfering with the growth of cancer cells, which are eventually destroyed.
Mechanism of actionAn inhibitor of tropomyosin receptor tyrosine kinases (TRKs) TRKA, TRKB, and TRKC (encoded by the neurotrophic tyrosine receptor kinase [NTRK] genes NTRK1, NTRK2, and NTRK3, respectively), proto-oncogene tyrosine-protein kinase ROS1 (ROS1), and anaplastic lymphoma kinase (ALK); also, inhibits JAK2 and TNK2. Major active metabolite of entrectinib, M5, showed similar in vitro activity against TRK, ROS1, and ALK. Fusion proteins that include TRK, ROS1, or ALK kinase domains can drive tumorigenic potential through hyperactivation of downstream signaling pathways, leading to unconstrained cell proliferation.
SafetyEntrectinib exhibits hepatic metabolism through cytochrome P450 (CYP) 3A and therefore interacts with moderate-strong CYP3A inhibitors and inducers. In addition, due to its effects on the QTcF interval, use of entrectinib should be avoided with other drugs known to prolong the QT/QTc interval.
PharmacologyEntrectinib, is a weak P-gp substrate that can sustain CNS exposure based on our novel in vitro and in vivo experiments. This is consistent with the observed preclinical and clinical efficacy of entrectinib in neurotrophic tropomyosin receptor kinase (NTRK) and ROS1 fusion-positive CNS tumors and secondary CNS metastases.
DescriptionEntrectinib (RXDX-101, Ignyta Pharmaceuticals, San Diego, CA, USA) is a small molecule that inhibits the tyrosine kinases TRKA/B/C, ROS1, and ALK (Table?1). It has a preclinical median inhibitory concentration (IC50) of 7?nm against ROS1, higher than crizotinib [95, 96]. Entrectinib was specifically designed to cross the blood-brain barrier [95].
Clinical UseEntrectinib demonstrated potent antitumor effects in tumor cell lines and patient-derived xenograft (PDX) tumor models in preclinical studies. Furthermore, entrectinib can cross the blood–brain barrier (BBB) to impact primary brain tumors and brain metastases in patients with NTRK1/ NTRK2/NTRK3, ROS1, and ALK fusion-driven cancers.
Tag:Entrectinib(1108743-60-7) Related Product Information
Afatinib (BIBW 2992) Lorlatinib (PF-06463922) lenvatinib Mesylate Dabrafenib Dacomitinib (PF299804) 4-[4-[[[[4-Chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-3-fluorophenoxy]-N-methyl-2-pyridinecarboxamide hydrate Brigatinib Trametinib Regorafenib Neratinib Poziotinib (HM781-36B) Cabozantinib Malate Cediranib Maleate Crizotinib AZD-9291 Nintedanib Ethanesulfonate Salt Olaparib Vandetanib